Knowing how durvalumab's perioperative effects were studied in the AEGEAN study.

Published Date: 13 Sep 2023

According to the research presented, giving patients with resectable NSCLC perioperative durvalumab in addition to neoadjuvant chemotherapy did not have a negative effect on surgery and was associated with a tolerable surgical safety profile.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Cancer mortality continuing to decline, says report

2.

Radionuclide-Containing Combo Slows Metastatic Prostate Cancer, Improves Survival

3.

Financial hardship common in patients with cancer

4.

The standard for high-risk prostate cancer is supported by a study using high-dose RT and long-term ADT.

5.

Advancing Health in Africa


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot